RT Journal Article
SR Electronic
T1 Machine learning detects SARS-CoV-2 and variants rapidly on DNA aptamer metasurfaces
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.07.21261749
DO 10.1101/2021.08.07.21261749
A1 Torun, Hulya
A1 Bilgin, Buse
A1 Ilgu, Muslum
A1 Yanik, Cenk
A1 Batur, Numan
A1 Celik, Suleyman
A1 Ozturk, Meric
A1 Dogan, Ozlem
A1 Ergonul, Onder
A1 Solaroglu, Ihsan
A1 Can, Fusun
A1 Onbasli, Mehmet Cengiz
YR 2021
UL http://medrxiv.org/content/early/2021/08/08/2021.08.07.21261749.abstract
AB COVID-19 is detected using reverse transcription polymerase chain reaction (RT-PCR) of nasal swabs. A very sensitive and rapid detection technique using easily-collected fluids like saliva must be developed for safe and precise mass testing. Here, we introduce a metasurface platform for direct sensing of COVID-19 from unprocessed saliva. We computationally screen gold metasurfaces out of a pattern space of 2100 combinations for strongly-enhanced light-virus interaction with machine learning and use it to investigate the presence and concentration of the SARS-CoV-2. We use machine learning to identify the virus from Raman spectra with 95.2% sensitivity and specificity on 36 PCR positive and 33 negative clinical samples and to distinguish wild-type, alpha, and beta variants. Our results could pave the way for effective, safe and quantitative preventive screening and identification of variants.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThe study has not been registered yet on clinicaltrials.gov, but we registered our clinical trial with Turkish Ministry of Health form number “Mehmet Cengiz Onbaşlı-2020-05-12T06_43_14” under COVID-19 Scientific Research Platform (“Bilimsel Araştırma Platformu”, https://bilimselarastirma.saglik.gov.tr/ )Funding StatementFunding support from Turkish Institutes of Health grant no. 7118-8798, Turkish National Academy of Sciences GEBIP Award 2019 (MCO) and The Scientific and Technological Research Council of Turkey grant 119S362 (İS, MCO) are gratefully acknowledged.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:We received Koc University Institutional Review Board (IRB) approval number 2020.112.IRB1.023, which covers all steps of sample collection, informed consent of the volunteers who donated nasopharyngeal and saliva samples at Koc University Hospital's Koc University Clinical Trial Unit.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used in this study are available from the corresponding author upon request. Institutional Review Board (IRB) approval 2020.112.IRB1.023 restricts the authors from disclosure of patient information or saliva samples. All scripts of this study are available under https://github.com/onbasli/KU-SARS-CoV-2-biosensor/ project GitHub repository.